DELTICOM-AG/YOURTYRES
29.9.2016 14:00:50 CEST | Business Wire | Press release
Just in time for the start of the winter season, Yourtyres.co.uk is extending its online shop to include yet more convenient features. For tyre dealers and workshops, this means that purchasing tyres in the online B2B shop provided by Delticom, Europe’s largest online tyre dealer, will be even easier and quicker than before.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160929005678/en/
In future, the following options will aid dealer partners of Yourtyres.co.uk to find the right tyres:
Even more convenient tyre search based on car model:
You can now search via match code, tyre number or via car model, a totally new search option. The search results display at a glance which tyres are approved for the customer’s car.
Bonus for car dealerships:
Especially for car dealerships, at Yourtyres.co.uk searching for original equipment (OE) is now possible as well as searching via the respective car model.
Customer reviews with tyre details:
This is also a new feature: From now on, all customer reviews from tyre testing platform Tyretest.com will be displayed on the relevant product pages at Yourtyres.co.uk . Dealer partners of Yourtyres.co.uk will thus have access to countless opinions and tips when selecting tyres and advising customers. At Tyretest.com , customers review many tyres that don’t make it to the major magazines. Even cheap tyres often perform well here, as the price-performance ratio is good and the overall result is therefore positive.
“We see ourselves as partners to our dealer customers. That’s why, on top of offering good prices, we want the new shopping functions to make shopping on Yourtyres.co.uk as simple and convenient for them as possible”, explains Thorsten Orbach, Head of Merchant Business at Delticom B2B and Yourtyres.co.uk . “For many commercial customers, one thing is particularly important: flexibility. Thanks to our large product range and our in-house warehouse stock, our partners can provide products at short notice for all their customer groups and vehicles. We offer speedy delivery and fantastic flexibility. There are no minimum order quantities or ordering fees, and we offer a variety of payment methods and return options.”
“In addition to the shop’s many convenient functions and countless shopping benefits for dealers, our new Delticom B2B services offer great potential for attracting new customers and additional business”, expands Andreas Faulstich, Head of B2B at Delticom AG, the partnership trading model. “The ability to co-operate as a fitting partner enables workshops to expand their business to include customers who buy their tyres in B2C shops such as Mytyres.co.uk .”
About Yourtyres.co.uk
Yourtyres.co.uk is an exclusive British online store from Delticom AG for workshops, retailers, wholesalers, tyre fitters/service stations and car accessories. With over 15 years of expertise in the online tyre business, the specialist B2B team of www.yourtyres.co.uk offers its customers a spectacular range of car and motorbike tyres of all brands and dimensions for all types of vehicles, tyres for light trucks, trucks and buses, custom tyres, complete wheel sets, car spare parts and accessories, engine oil and batteries. In addition to favourable purchasing conditions, retail customers benefit from the online shop’s time-saving tyre search function, high availability, reliable delivery thanks to in-house warehouses as well as a simple registration process with no hidden costs - from the very first tyre.
Online shop for dealers and workshops in the UK: www.yourtyres.co.uk and 26 other countries.
Information about the company : www.delti.com
Tyre tests : www.tyretest.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005678/en/
Contact:
Press contact:
insignis Agentur für
Kommunikation GmbH
(GPRA)
Henning Jahns
Tel.: +49-511-132214-14
Fax:
+49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom